Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity - PubMed
5 hours ago
- #Tirzepatide
- #clinical safety
- #metabolic diseases
- Tirzepatide is a dual GIP and GLP-1 receptor agonist with strong efficacy for type 2 diabetes and obesity.
- It shows potential therapeutic benefits in cardiovascular diseases, metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic kidney disease.
- Cardiorenal benefits are supported by high-level outcome trials, while evidence for hepatic, renal, and musculoskeletal effects is preliminary.
- Safety concerns exist, with evidence based on case reports, post hoc analyses, and non-prespecified endpoints, necessitating further large-scale studies.
- Continued pharmacovigilance is crucial to identify and mitigate adverse drug reactions, especially rare serious events.